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Abstract
Background: Validated biomarkers in head and neck squamous cell carcinoma
(HNSCC) are scarce.
Methods: We retrospectively analyzed 62 patients with HNSCC treated with
radiotherapy +/ concurrent chemotherapy. Pretreatment metabolic tumor
volume (MTV) and total lesion glycolysis (TLG) were measured in a 18F-FDG
positron emission tomography using a liver dependent standardized uptake
value threshold. Cox regression analyses were performed to find associations
with disease-free survival (DFS) and overall survival (OS).
Results: High values of MTV (>37 ml) were independently associated with a
worse DFS (hazard ratio [HR] = 3.45; 95% confidence interval [CI], 1.52–7.84)
and OS (HR = 3.27; 95% CI, 1.41–7.57). Similar results were found for high
values of TLG (>247 g) for DFS (HR = 3.32; 95% CI, 1.44–7.65) and OS
(HR = 3.42; 95% CI, 1.45–8.07).
Conclusions: MTV and TLG can be considered as independent prognostic fac-
tors for DFS and OS in patients with HNSCC. Considering how easily obtain-
able they are, they may be useful for predicting clinical outcomes in these
patients.
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1 | INTRODUCTION
Head and neck cancer (HNC) accounts for more than
330 000 deaths annually and it is newly diagnosed in approx-
imately 650 000 patients every year, making it the sixth most
common cancer worldwide.1,2 Nonetheless its relevance,
there are still many controversies and discrepancies among
practitioners surrounding the therapeutic approaches for
these patients, especially in locally advanced HNC. 3-5 The
two main tools to categorize patients with HNC and to assess
treatment and prognosis are the Union Internationale Contre
le Cancer (UICC) TNM classification and the American Joint
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Committee on Cancer (AJCC) staging system. Although
practical, those strategies focus only on morphological
criteria and do not consider characteristics inherent to each
tumor.6,7 Up to this point, human papilloma virus (HPV) sta-
tus and its surrogate marker P16 (CDKN2A) are the only
two validated biomarkers in HNC, particularly in the oro-
pharynx.8-10 Therefore, finding markers that could aid in
predicting clinical outcomes and in treatment planning is of
utter interest.
Ever since the introduction of fluorine-18-
fluorodeoxyglucose (18F-FDG) positron emission
tomography (PET) for staging, treatment planning,
and monitoring patients with HNC, the relevance of
this imaging technique has been exponentially
increasing because of its ability to evaluate both
tumor morphology and biological activity.11-13 Fur-
thermore, several quantitative PET parameters are
being studied as prognostic factors in HNC. Among
them, maximum standardized uptake value (SUVmax)
is the parameter most widely used, primarily owing to
how easily measured it is with current PET machines.
Nonetheless, conflicting results on its prognostic
value are being found in many studies.7,14-17 Other
parameters such as metabolic tumor volume (MTV)
and total lesion glycolysis (TLG) are showing good
prognostic value with more homogeneous results than
SUVmax.
7,14,18-20 Even so, these parameters have sev-
eral limitations to consider. In order to measure MTV
and TLG, it is necessary to decide on one of the several
segmentation methods available to define the volume of
interest (VOI) as there is no consensus on which to use.
Because of its practicality, a fixed threshold of a, in gen-
eral, 40%–50% of SUVmax and an isocontour based on a
fixed SUV threshold (usually SUV = 2.5) are the most
widely used methods.21-25 Both measurements are SUV
dependent and therefore affected by its variations. The
accuracy of the image reconstruction and correction algo-
rithms, PET scanner's signal-to-noise properties, 18F-FDG
uptake time, tumor size, patients' weight and blood glu-
cose levels, among others factors, have a direct impact in
SUV measurements, making it difficult to reproduce them
properly.25-27 To minimize this variability, many authors
recommend using the SUV of a reference region as thresh-
old.24,26-29 Because of the stability over time of the SUV in
the liver and mediastinum, those are the two main refer-
ence regions used for thresholding.26,27,30,31
The aim of this study is to measure pretreatment
MTV and TLG calculated using a liver SUVmean-
dependent parameter and analyze their association with
disease-free survival (DFS) and overall survival (OS) in
patients diagnosed with locally advanced head and neck
squamous cell carcinoma (HNSCC) treated with radio-
therapy +/ concomitant chemotherapy.
2 | MATERIALS AND METHODS
2.1 | Study population
We retrospectively reviewed biopsy-confirmed patients
with HNSCC who were treated at Puerta de Hierro Uni-
versity Hospital between January 2012 and December
2018. The inclusion criteria were: adult patients
(≥18 years of age) with the primary diagnosis of stage
III/IV HNSCC without distant metastasis who had
undergone pretreatment 18F-FDG PET-computed tomog-
raphy (CT) for treatment planning and initial staging that
had been treated with radiotherapy alone or with concur-
rent chemoradiotherapy. Patients with nasopharyngeal
cancer, patients who had undergone previous treatments,
and patients with coexisting malignancies were excluded.
Patients with an interval between 18F-FDG PET-CT
acquisition and treatment initiation longer than 6 weeks
were also excluded. Approval for this study was granted
by the Institutional Ethics Committee of our hospital. In
consequence of the retrospective design of the review,
informed consent from each patient was waived.
2.2 | Radiation therapy and follow-up
Patients were simulated in supine position and immobili-
zation was carried out with a thermoplastic head-
shoulders mask. Contrast-enhanced planning CT with
3 mm slice thickness was acquired. PET-CT was per-
formed in all patients and was registered with planning
CT to aid in the delineation of treatment volumes. For
each patient, the following clinical target volumes (CTVs)
were defined: CTV1 included the primary and pathologi-
cal neck nodes gross tumor volumes (GTV); CTV2
included the CTV1 and the “high risk” first uninvolved
lymph-node level; and CTV3 included elective bilateral
lymph nodes regions according to published interna-
tional guidelines.32 The corresponding planning target
volumes (PTVs) were generated by adding 0.5 mm to the
CTVs. Treatment was administered in 32 fractions using
the simultaneous integrated boost up to doses of 69.12,
57.6, and 53.12 Gray (Gy) for PTV1, PTV2, and PTV3,
respectively. Treatment with intensity modulated radia-
tion therapy was administered in a TomoTherapy HiArt
unit equipped with an image-guided radiation therapy
system. Dose-limiting constraints for organs at risk were
the following: Dmax of 45 Gy for spinal cord; V28 < 50%
for parotid glands; V65 < 10% for mandible; Dmax of
55 Gy for brain stem; and Dmean < 50 Gy for constrictor
muscles. Concomitant cisplatin-based chemotherapy was
administered in most patients with two protocols: a regi-
men consisting of cisplatin plus oral tegafur described
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elsewhere,33 and a regimen of six cycles of weekly cis-
platin (40 mg/m2). Cetuximab (400 mg/m2 initial dose,
followed by seven weekly doses at 250 mg/m2) was
administered in patients who were not suitable for a
cisplatin-based protocol. Radiotherapy alone was admin-
istered in the patients whose physical conditions were
not optimal for chemotherapy.
To assess treatment response, 18F-FDG PET-CT was
performed between 2 and 4 months after therapy comple-
tion. Head and neck imaging with CT or magnetic reso-
nance imaging and physical examination were performed
every 6 months for 3 years and once a year for two more
years. In case of persistent disease or recurrence, salvage
surgery or palliative treatment was indicated.
2.3 | 18F-FDG PET-CT imaging
Patients were asked to fast for at least 6 h until their
serum glucose concentration was less than 180 mg/dl
prior i.v. 18F-FDG (approximately 350–400 MBq)
injection. CT scans were performed with a helical
multidetector CT as follows: 110 kVp, a maximum modu-
lated milliamperage of 85 mAs, six slices with a 5.0 mm
thickness, and no i.v. or oral contrast, from the top of the
skull to the mid-tight. CT data were used for attenuation
correction and image fusion. PET-CT image acquisition
was performed after 50–60 min of i.v. injection with
a multimodality Siemens Biograph 6 scan (Biograph;
Siemens, Erlangen, Germany) as follows: 4-min scan per
bed position  7–8 positions and ordered-subset expecta-
tion maximization reconstruction (four iterations, eight
subsets).
2.4 | Image interpretation
18F-FDG findings were transferred into Siemens Leonardo
reading station and analyzed by an experienced nuclear
medicine physician (J. Mucientes) who was blinded to all
patients' clinical outcomes, using the program Syngo®.via
(Siemens Healthineers, Muenchen, Germany). Image
voxels were converted into standardized uptake values.
SUV is a decay-corrected measurement of activity per unit
of mass of tissue adjusted for administered activity per unit
of body weight.34 For measuring the VOIs, we selected a
background-level threshold method using the liver as the
reference region. Liver SUVmean was calculated by placing
a 3 cm sphere on the center of its VIII segment.24,26-28
Targeted 18F-FDG-avid lesions were manually delimited in
three imaging planes and all lesions (tumor and metastatic
lymph nodes) with a SUV higher than liver SUVmean + 2
standard deviations (SDs) isocontour were marked as the
VOIs. The software program automatically calculated the
MTV of tumor and/or pathologic lymph nodes and both
volumes were then combined. TLG was therefore obtained
using the formula: MTV  Liver SUVmean.
2.5 | Statistical analysis
Descriptive analysis for categorical variables was per-
formed with means of absolute and relative frequencies;
numerical variables were analyzed through means with
standard deviation, medians with percentiles 25 and
75 (P25-P75), and minimum and maximum values.DFS
was defined as the time between treatment initiation and
relapse or death from any cause, whichever occurs first.
Overall survival was defined as the time between treat-
ment initiation and death from any cause. Patients who
were followed-up until the end of the study with no
events were considered as censored. Survival function
was estimated through the Kaplan–Meier method. Differ-
ences between survival curves were compared through
the log-rank test. We analyzed local control rate consider-
ing the death as a competing event; therefore, cumulative
incidence function (CIF) was estimated instead of
Kaplan–Meier curve.
The area under the curve (AUC) receiver operating
characteristics (ROC) is a useful approach that represents
the overall performance of a biomarker. In clinical prac-
tice, biomarkers with AUC–ROC curves >0.9 are consid-
ered very accurate; moderately accurate for AUCs
between 0.7 and 0.9; slightly accurate for AUCs of 0.5–0.7
and no better than chance accuracy with an AUC <0.5.
In order to obtain an optimal cutoff point for each one
of the parameters (MTV and TLG) and the outcomes
(OS and DFS), time-dependent ROC curves for survival
data were developed.35 Youden and Liu methods were
used to define the optimal cut point. The Youden index
method defines the optimal cut point as the point maxi-
mizing the difference between true positive rate and
false positive rate over all possible cut-point values.36
Liu's method defines the optimal cut point as the point
maximizing the product of sensitivity and specificity.37
Then, to measure the prognostic value for each one of
the parameters, we executed two Cox proportional hazard
models: a dichotomized one with the optimal cut points
and a continuous one. Firstly, we developed a univariable
approach, and secondly, a multivariable model adjusting
by T classification, N classification, and age. Schoenfeld
residuals were used to check the proportional hazards
assumption. Univariable subanalyses per disease location
were also developed and multivariable subanalyses were
performed for the locations with a significant statistical
association in their univariable analysis.
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To test the goodness of fit and performance of the
models, Harrell's C index (C-index) and Akaike informa-
tion criterion (AIC) were estimated, respectively. Values
of C-index near 0.5 indicate that the risk score predic-
tions are no better than flip a coin in determining which
patient will make the event. Values near 1 indicate that
the model is good at determining between two patients
who will have an event first. AIC estimates the relative
amount of information lost by a given model: the less
information a model loses, the higher the quality of that
model. Given a set of candidate models for the data, the
preferred model is the one with the minimum AIC value.
Significance level was set at 0.05. Software used was Stata
16 (StataCorp. 2019. Stata Statistical Software: Release 16.
College Station, Texas: StataCorp LLC).
3 | RESULTS
3.1 | Patient' characteristics
We retrieved the records of 79 patients diagnosed with
stage III-IV HNSCC. We excluded 15 patients because
pretreatment 18F-FDG PET-TC had been performed in a
different center and two because of a longer than 6 weeks
interval between PET acquisition and treatment initiation.
Thus, 62 records were eligible for the analysis. Patients'



































Grade 1 6 (10)
Grade 2 23 (37)
Grade 3 15 (24)
Treatment
Radiotherapy alone 3 (5)
Chemoradiotherapy 59 (95)
Cisplatin + tegafur 31 (50)







<66 Gy 3 (5)
≥66 Gy 59 (95)
Chemotherapy percentage
None or <80% 17 (27)
≥80% 45 (73)
Follow-up information
Median follow-up, months 59.3 (48.6–68.5)a
Survival information
Locoregional recurrences 21 (34)
Distant metastasis 13 (21)
4-year DFS 57 (43–69)a
4-year OS 63 (49–74)a
Abbreviations: DFS, disease-free survival; Gy, gray; HPV, human papilloma
virus; N, lymph nodes; ns, not stated; OS, overall survival; T, tumor.
a95% confidence interval.
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characteristics are summarized on Table 1. At the moment
of the analysis, 25 deaths (40%) had occurred: 19 died with
disease and 6 from other causes. Five patients were alive
with disease. Twenty-one patients (34%) had locoregional
recurrences and 13 (21%) developed distant metastasis.
Local and locoregional control per disease location are
shown in Table S1. Two patients died during treatment
and, after a severe cervical radiodermatitis, another patient
refused to complete the doses. Median follow-up was
59 months (95% confidence interval [CI], 48.6–68.5) with a
4-year DFS and OS for the whole cohort of 57% and 63%,
respectively. Four-year DFS and OS per disease location
are presented in Table S2.
3.2 | PET parameters and cutoff values'
determination
The median MTV, TLG, and SUVmax values were
16.09 ml (range, 0.08–132.04 ml), 104.75 g (range, 0.35–
2412.89 g), and 12.74 (range, 3.0–30.57), respectively.
Cutoff values acquired through the time-dependent
TABLE 2 Univariable Cox regression analysis for disease-free survival and overall survival
Overall survival Disease-free survival
Variables HR (95% CI) p-value HR (95% CI) p-value
Age (years) 1.03 (0.99–1.07) 0.111 1.01 (0.99–1.05) 0.484
Sex
Female 1 1
Male 1.17 (0.44–3.14) 0.749 1.22 (0.46–3.26) 0.688
Smoking
Yes 1 1
No 0.76 (0.28–2.03) 0.587 1.14 (0.39–3.31) 0.815
T-classification
T1–T2 1 1
T3–T4 1.43 (0.57–3.59) 0.445 1.46 (0.58–3.67) 0.419
N-classification
N0 1 1
N+ 1.08 (0.40–2.93) 0.874 1.23 (0.46–3.29) 0.677
Overall TNM stage
III 1 1
IVa 1.04 (0.42–2.58) 0.942 1.58 (0.60–4.17) 0.352
IVb 2.02 (0.70–5.86) 0.196 2.25 (0.72–7.00) 0.162
Histologic differentiation
Grade 1–2
Grade 3 1 1
1.48 (0.52–4.19) 0.459 1.06 (0.39–2.87) 0.909
Radiotherapy dose (Gy)
<66 1 1
≥66 0.77 (0.10–5.74) 0.799 1.0 (0.13–7.44) 0.997
Chemotherapy %
<80% 1 1
≥80% 0.51 (0.23–1.14) 0.102 0.70 (0.29–1.69) 0.432
SUVmax
≤12.63 1 1
>12.63 1.63 (0.73–3.62) 0.235 2.40 (1.05–5.44) 0.037
Abbreviations: CI, confidence interval; Gy, gray; HR, hazard ratio; N, lymph nodes; SUVmax, maximum standardized uptake value; T, tumor.
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AUC-ROC were estimated at a 3-years' time point for
MTV, TLG, and SUVmax. The cutoff points were 37 ml
(AUC = 0.68), 247 g (AUC = 0.66), and 12.63
(AUC = 0.62), respectively. The same cutoff points were
obtained with both Youden and Liu method. Thus, MTV,
TLG, and SUVmax were dichotomized according to their
corresponding cutoff values.
3.3 | Survival analysis
Univariable analyses for SUVmax (hazard ratio
[HR] = 2.40, 95% CI = 1.05–5.44, p = 0.037), dichoto-
mized MTV (HR = 3.62, 95% CI = 1.63–8.03, p = 0.002)
and TLG (HR = 3.28, 95% CI = 1.48–7.25, p = 0.003), as
well as continuous MTV (HR = 1.25, 95% CI = 1.11–1.41,
p ≤ 0.001) and TLG (HR = 1.03, 95% CI = 1.01–1.05,
p ≤ 0.001) had a significant association with DFS
(Tables 2 and 3). Both dichotomized (HR = 3.15, 95%
CI = 1.41–7.04, p = 0.005) and continuous (HR = 1.19,
95% CI = 1.07–1.33, p = 0.002) measurements of MTV,
as well as dichotomized (HR = 2.82, 95% CI = 1.23–6.21,
p = 0.010) and continuous (HR = 1.04, 95% CI = 1.01–
1.06, p = 0.001) measurements of TLG were associated
with OS (Table 4). This trend was maintained for both OS
and DFS in the patients with hypopharynx/larynx and
oropharynx cancers, although the results for the later loca-
tion were not statistically significant (Tables S3 and S4).
TABLE 3 Disease-free survival Cox regression analyses for MTV and TLG
Univariable analysis Multivariable analysisa
HR (95% CI) p-value HR (95% CI) p-value C-index AIC
Dichotomized MTV model
≤37 ml 1 1
>37 ml 3.62 (1.63–8.03) 0.002 3.45 (1.52–7.84) 0.003 0.673 185.065
Continuous MTV model
Per 10-ml increment 1.25 (1.11–1.41) <0.001 1.25 (1.09–1.42) 0.001 0.676 183.450
Dichotomized TLG model
≤247 g 1 1
>247 g 3.28 (1.48–7.25) 0.003 3.32 (1.44–7.65) 0.005 0.675 185.465
Continuous TLG model
Per 25-g increment 1.03 (1.01–1.05) <0.001 1.03 (1.01–1.05) 0.001 0.677 186.081
Abbreviations: AIC, Akaike information criterion; CI, confidence interval; C-index, Harrell's C-index; g, gram; HR, hazard ratio; ml, milliliter; MTV, metabolic
tumor volume; TLG, total lesion glycolysis.
aAdjusted by age, T-classification, and N-classification.
TABLE 4 Overall survival Cox regression analyses for MTV and TLG
Univariable analysis Multivariable analysisa
HR (95% CI) p-value HR (95% CI) p-value C-index AIC
Dichotomized MTV model
≤37 ml 1 1
>37 ml 3.15 (1.41–7.04) 0.005 3.27 (1.41–7.57) 0.006 0.673 183.609
Continuous MTV model
Per 10-ml increment 1.19 (1.07–1.33) 0.002 1.21 (1.07–1.36) 0.002 0.676 182.434
Dichotomized TLG model
≤247 g 1 1
>247 g 2.82 (1.28–6.21) 0.010 3.42 (1.45–8.07) 0.005 0.696 182.984
Continuous TLG model
Per 25-g increment 1.04 (1.01–1.06) 0.001 1.04 (1.02–1.06) 0.001 0.663 182.269
Abbreviations: AIC, Akaike information criterion; CI, confidence interval; C-index, Harrell's C-index; g, gram; HR, hazard ratio; ml, milliliter; MTV, metabolic
tumor volume; TLG, total lesion glycolysis.
aAdjusted by age, T-classification, and N-classification.
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Multivariable analyses for both models of MTV and TLG
in the patients with hypopharynx/larynx cancer obtained
a significant association with OS and DFS (Table S5). Oral
cavity cancers and oropharynx subgroups analysis per
HPV status were not estimable because of the small sam-
ple size in those analyses (Tables S3 and S4).
In the multivariable analyses for DFS, MTV and TLG
measurements remained as independent prognostic fac-
tors. Patients with >37 ml MTV had higher hazard for
recurrence (HR = 3.45, 95% CI = 1.52–7.84, p = 0.003)
than patients with a ≤37 ml MTV. The same happened
with patients with a >247 g TLG (HR = 3.32, 95%
CI = 1.44–7.65, p = 0.005). HR for DFS was 1.25 (95%
CI = 1.09–1.42, p = 0.001) for every 10-ml increment of
MTV and 1.03 (95% CI = 1.01–1.05, p = 0.001) for every
25-g increment of TLG. AIC and C-index values are
shown in Table 3.
Measurements for MTV and TLG also stayed as inde-
pendent prognostic factors in the multivariable analyses
for OS. Patients with >37 ml MTV had a higher hazard
for death (HR = 3.27, 95% CI = 1.41–7.57, p = 0.006)
than patients with a ≤37 ml MTV. Equivalent results
were found for patients with >247 g TLG (HR = 3.42
(95% CI = 1.45–8.07, p = 0.005). HR for death was 1.21
(95% CI = 1.07–1.36, p = 0.002) for every 10-ml incre-
ment of MTV and 1.04 (95% CI = 1.02–1.06, p = 0.001)
for every 25-g increment of TLG. AIC and C-index are
shown in Table 4.
Kaplan–Meier's curves for DFS as well as OS using
the MTV and TLG with the cutoff points of the dichoto-
mized models are shown in Figure 1. CIF of local control
for the same models are shown in Figure 2.
4 | DISCUSSION
We retrospectively found an independent association
between pretreatment MTV and TLG with survival in
HNSCC as higher values of these parameters predict a
worse DFS and OS. According to C-index results, all
FIGURE 1 Kaplan–Meier's curves for disease-free survival (DFS) and overall survival (OS) using the metabolic tumor volume (MTV)
and total lesion glycolysis (TLG) dichotomized models. A, Curves for DFS and a cutoff of 50 ml of MTV. B, Curves for DFS and a cutoff of
284 g of TLG. C, Curves for OS and a cutoff of 50 ml of MTV. D, Curves for OS and a cutoff of 284 g of TLG [Color figure can be viewed at
wileyonlinelibrary.com]
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models created for MTV and TLG behaved as good
models. Among them, continuous MTV model was
superior for predicting DFS and continuous TLG model
was superior for predicting OS, as per AICs results
(Tables 3 and 4). This independent association was espe-
cially maintained in the subanalysis of patients with
hypopharynx/larynx cancer, with good C-index results
(Table S5).
In the last decades, the number of publications study-
ing the prognostic value of MTV and TLG in HNSCC is
increasing and the results are in general homogeneous,
suggesting a good prognostic potential.7,14,18 Pak et al,7
Bonomo et al,14 and Xie et al18 have performed meta-
analyses (MAAs) whose results indicate a significant
association between MTV and survival in HNSCC. The
MAA performed by Pak et al7 also suggest the same for
TLG. Our previous MAA had similar results for both
markers as well.38
UICC TNM classification and AJCC staging system
are the two standardized tools globally used for treatment
evaluation and survival prediction in HNC. These sys-
tems describe the extension of the disease based on its
morphological characteristics, presenting a descriptive
analysis in a short and precise code.6 Notwithstanding
their practicality, these classification methods do not take
into consideration biological features inherent to each
tumor, thus limiting their prognostic capability.3,39,40 As
the relevance of nonmorphologic factors within tumors is
being recognized, it might be interesting to consider the
possibility of including them in a comprehensive classifi-
cation system.3
Although metabolic parameters have consistently
shown a good prognostic value for HNC in many studies,
these measurements have numerous limitations to con-
sider. There are several segmentation methods to delineate
VOIs: manual selection, based on a background-level
threshold (e.g., relevant background SUV + 2–3 SDs), gra-
dient based methods, a threshold based on a percentage of
SUVmax (e.g., 40%–50%), an isocontour based on a fixed
SUV threshold (e.g., SUV = 2.5), among others.21-24,26 The
latter two are the most widespread methods used, particu-
larly because they are easily obtainable with current PET
machines. As mentioned earlier in this study, these
methods are SUV-dependent and thus affected by the
quality of the PET machine, image analysis, and patients'
characteristics and preparation, limiting the possibility
to reproduce and generalize those measurements.25,31,41-43
In consequence and to minimize this variability, many
authors recommend using a gradient-based segmentation
method40,42,44 or to use the SUV of a reference region for
thresholding,26,28-30 being the liver and the mediastinum
the two regions more widely used.27,29,30 Taking all this
into consideration, in order to obtain reproducible and gen-
eralizable cutoff values, there has to be a thorough and
meticulous standardization in PET preparation. Among all
44 studies analyzing MTV in HNSCC included in the four
MAAs published to this date,7,14,18,38 only two of them used
the SUV of a reference region for segmentation, and both
studies chose the mediastinum.45,46 During the manual sea-
rch of our literature review, 38 we found one paper that
used liver's SUV for thresholding.24 However, as this last
study was comparing several segmentation methods and
they found no significant differences between them, their
survival analysis was also made using the mediastinum as
the reference region. To the best of our knowledge, this is
the first study in HNSCC using the liver's SUV for
thresholding MTV. Although this method is proposed in the
PET Response Criteria in Solid Tumors 1.0 (PERCIST),26 it
is not commonly used in HNSCC papers.
This study has several limitations, primarily because
of the limited number of patients with heterogeneous dis-
eases, as well as its retrospective design with potential
biases in data collection. Nevertheless, these variables
seemed to offer important pretreatment information that
could aid in monitoring recurrence and even in treatment
planning.
FIGURE 2 Cumulative incidence function of local control
using the metabolic tumor volume (MTV) and total lesion
glycolysis (TLG) dichotomized models. A, Cumulative incidence for
MTV and local control; B, cumulative incidence for TLG and local
control [Color figure can be viewed at wileyonlinelibrary.com]
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We have found a significant and independent associa-
tion between MTV and TLG with the survival of patients
with hypopharynx/larynx cancer, agreeing with the
results of other studies.47-49 The great morbidity,
stigma, and decrease in quality of life associated with
the treatment of cancer in these locations require a
comprehensive analysis when deciding between an
organ preservation strategy or primary surgery. Yabuki
et al50 performed a prospective study comparing the
survival rate of patients with laryngeal cancer and high
MTV according to the treatment strategy selected for
each case (surgery-based vs. radiation-based). The
study found a better survival rate for the patients who
were treated with a surgery-based therapy. These
results point to the possibility of MTV being able to
help decide between treatments, and it might even
throw some light into the existing controversies in
HNC treatment strategy selection.4,5
Many prospective and multicentric trials are still
required to consider modifying the standardized proto-
cols for managing patients with HNC. Nevertheless, and
with all due limitations, pretreatment MTV and TLG
offer valuable information that can aid in selecting
patients who would benefit from a more thorough follow
up for early recurrence detection and, perhaps in the
future, may also aid in treatment strategy selection.50
5 | CONCLUSIONS
The results of this study suggest an independent associa-
tion of pretreatment MTV and TLG with DFS and OS in
patients diagnosed with locally advanced HNSCC treated
with radiotherapy +/ chemotherapy. Considering how
easily obtainable they are with current technology, and
despite their limitations, these parameters can be used to
identify patients with a higher risk of recurrence.
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